NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2016 (the first quarter of fiscal 2017), compared with the three months ended September 30, 2015. The filing is dated November 14, 2016.
Business context
NanoViricides is a pre-revenue, development-stage antiviral biopharmaceutical company. Its drug candidates remain in preclinical or advanced preclinical development; it has no commercialized products. Management prioritized topical herpes-virus programs, particularly a shingles treatment, while also advancing injectable influenza treatment and other programs.
Financial performance and position
- Revenue: None in either comparable quarter. Accordingly, a revenue margin is not applicable.
- Operating expenses: $2.44 million, up from $2.23 million. Research and development was $1.45 million, up from $1.28 million; general and administrative expense was $988,312, up from $942,979.
- Loss: Operating loss was $2.44 million versus $2.23 million. Net loss was $3.06 million ($0.05 per share), compared with $1.31 million ($0.02 per share).
- Cash flow: Operating activities used $2.22 million, versus $1.65 million a year earlier. Capital expenditures were $24,435, versus $333,664. Cash declined by $2.25 million during the quarter to $21.91 million.
- Liquidity and equity: Current assets were $22.12 million and current liabilities were $6.94 million. Total assets were $34.22 million; stockholders’ equity was $20.23 million. Accumulated deficit was $67.89 million.
- Debt and other liabilities: The balance sheet reports Series B debentures, net of discount, of $5.69 million and Series C debentures, net of discount, of $3.32 million. The underlying principal amounts are $6 million and $5 million, respectively. Series B matures February 1, 2017; Series C matures June 30, 2018. Total liabilities were $14.00 million, including $3.73 million of derivative liabilities.
- Related-party exposure: A director is owed $9 million of Series B and Series C debenture principal. The company also reported $658,439 payable to TheraCour Pharma, a related party, and $861,616 of R&D costs paid to TheraCour during the quarter.
Changes versus the prior comparable quarter
- Net loss increased by $1.75 million, while operating loss rose by $215,398.
- The principal factor affecting the comparison was derivative valuation: the prior-year quarter recorded $1.49 million of noncash derivative fair-value income, versus $13,291 in the current quarter. Convertible-debenture discount amortization also increased to $403,462 from $333,710.
- Operating cash use increased by approximately $571,000. Cash fell from $24.16 million at June 30, 2016 to $21.91 million at September 30, 2016.
Outlook, risks and unusual items
- Management stated that available cash should fund operations for more than one year at the current spending rate and could support toxicology and efficacy work, an IND or equivalent filing, and Phase I and Phase IIa trials for at least one candidate. These are estimates, not assured outcomes; management cited preliminary discussions and “soft” CRO quotes.
- The company expects continuing losses and no foreseeable revenue. Development timelines and costs may exceed estimates; unsuccessful studies could require further work, reprioritization, or additional financing. The company also acknowledged limited experience taking a drug through human clinical trials and dependence on external collaborators and service providers.
- Management identified the shingles topical candidate as potentially the earliest to enter clinical evaluation, with injectable FluCide expected later. No specific dates or formal financial guidance were provided. Facility validation, reproducible production batches, and regulatory requirements remain development dependencies.
- The $6 million Series B maturity in February 2017 creates a near-term repayment or conversion consideration. Management said any principal not converted would be payable in cash at maturity.
- The quarter included noncash compensation in shares and warrants. Derivative liabilities are Level 3 fair-value estimates based on unobservable assumptions. The company reported no pending or threatened legal proceedings and no off-balance-sheet arrangements during the period.
- Management concluded disclosure controls were effective at a reasonable-assurance level and reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the company can meet or refinance the $6 million Series B maturity due February 1, 2017, and the terms of any conversion or cash repayment.
- Whether cash burn, clinical-development costs, and actual CRO and manufacturing expenses remain consistent with management’s estimates and stated runway.
- Progress toward selecting a clinical candidate, completing IND-enabling studies, validating the manufacturing process, and filing an IND or equivalent application.
- The assumptions and potential dilution associated with convertible debentures, warrants, and derivative liabilities, including related-party financing and TheraCour balances.
- The filing describes the quarter ended September 30, 2016; investors should confirm the reporting period rather than rely on metadata labeling it “2016 Q1.”